I-Mab Shares Rise After Completing Enrollment in Givastomig Trial

Dow Jones

Aug 12

By Chris Wack

I-Mab shares were 13% higher, at $3.84, after the company said enrollment in its planned Phase 1b dose expansion cohorts evaluating givastomig in combination with nivolumab and mFOLFOX6 has been completed ahead of expectations.

The biotechnology company said the Phase 1b study is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig, a potential best-in-class, bispecific antibody, used with nivolumab and mFOLFOX6, as first line therapy in patients with positive gastric cancers.

The primary endpoint is safety. The dose expansion cohorts of the study enrolled a total of 40 patients across two doses--8 mg/kg and 12 mg/kg-- and enrolled only patients in the U.S.

The stock hit its 52-week high of $4.18 on Thursday, and is up 260% in the past 12 months.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

August 11, 2025 12:35 ET (16:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2558647276"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558647276\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558647276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 00:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558647276","market":"us","top_or_hot":-1,"title":"I-Mab Shares Rise After Completing Enrollment in Givastomig Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IMAB\">I-Mab</a> shares were 13% higher, at $3.84, after the company said enrollment in its planned Phase 1b dose expansion cohorts evaluating givastomig in combination with nivolumab and mFOLFOX6 has been completed ahead of expectations. \n</p>\n<p>\n  The biotechnology company said the Phase 1b study is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig, a potential best-in-class, bispecific antibody, used with nivolumab and mFOLFOX6, as first line therapy in patients with positive gastric cancers. \n</p>\n<p>\n  The primary endpoint is safety. The dose expansion cohorts of the study enrolled a total of 40 patients across two doses--8 mg/kg and 12 mg/kg-- and enrolled only patients in the U.S. \n</p>\n<p>\n  The stock hit its 52-week high of $4.18 on Thursday, and is up 260% in the past 12 months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 11, 2025 12:35 ET (16:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>I-Mab Shares Rise After Completing Enrollment in Givastomig Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nI-Mab Shares Rise After Completing Enrollment in Givastomig Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-12 00:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IMAB\">I-Mab</a> shares were 13% higher, at $3.84, after the company said enrollment in its planned Phase 1b dose expansion cohorts evaluating givastomig in combination with nivolumab and mFOLFOX6 has been completed ahead of expectations. \n</p>\n<p>\n  The biotechnology company said the Phase 1b study is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig, a potential best-in-class, bispecific antibody, used with nivolumab and mFOLFOX6, as first line therapy in patients with positive gastric cancers. \n</p>\n<p>\n  The primary endpoint is safety. The dose expansion cohorts of the study enrolled a total of 40 patients across two doses--8 mg/kg and 12 mg/kg-- and enrolled only patients in the U.S. \n</p>\n<p>\n  The stock hit its 52-week high of $4.18 on Thursday, and is up 260% in the past 12 months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 11, 2025 12:35 ET (16:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2558647276","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558647276","pubTimestamp":1754930100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"I-Mab shares were 13% higher, at $3.84, after the company said enrollment in its planned Phase 1b dose expansion cohorts evaluating givastomig in combination with nivolumab and mFOLFOX6 has been completed ahead of expectations.The biotechnology company said the Phase 1b study is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig, a potential best-in-class, bispecific antibody, used with nivolumab and mFOLFOX6, as first line therapy in patients with positive gastric cancers.The primary endpoint is safety. The dose expansion cohorts of the study enrolled a total of 40 patients across two doses--8 mg/kg and 12 mg/kg-- and enrolled only patients in the U.S.The stock hit its 52-week high of $4.18 on Thursday, and is up 260% in the past 12 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4526":"热门中概股","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓","BK4139":"生物科技","IMAB":"I-Mab"},"translate_title":"天境生物股价在完成Givastomig试验入组后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMAB":0.9},"content_text":"By Chris Wack \n\n\n \n\n\nI-Mab shares were 13% higher, at $3.84, after the company said enrollment in its planned Phase 1b dose expansion cohorts evaluating givastomig in combination with nivolumab and mFOLFOX6 has been completed ahead of expectations. \n\n\n  The biotechnology company said the Phase 1b study is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig, a potential best-in-class, bispecific antibody, used with nivolumab and mFOLFOX6, as first line therapy in patients with positive gastric cancers. \n\n\n  The primary endpoint is safety. The dose expansion cohorts of the study enrolled a total of 40 patients across two doses--8 mg/kg and 12 mg/kg-- and enrolled only patients in the U.S. \n\n\n  The stock hit its 52-week high of $4.18 on Thursday, and is up 260% in the past 12 months. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 11, 2025 12:35 ET (16:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}